Home » Stocks » Veru Inc.

Veru Inc. (VERU)

Stock Price: $3.06 USD -0.03 (-0.97%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed
After-hours: $3.00 -0.06 (-1.96%) Aug 7, 7:09 PM

Stock Price Chart

Key Info

Market Cap 208.10M
Revenue (ttm) 38.98M
Net Income (ttm) -9.95M
Shares Out 69.86M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $3.06
Previous Close $3.09
Change ($) -0.03
Change (%) -0.97%
Day's Open 3.07
Day's Range 2.98 - 3.08
Day's Volume 441,374
52-Week Range 1.67 - 4.74

More Stats

Market Cap 208.10M
Enterprise Value 215.81M
Earnings Date (est) Aug 13, 2020
Ex-Dividend Date n/a
Shares Outstanding 69.86M
Float 49.54M
EPS (basic) -0.15
EPS (diluted) -0.15
FCF / Share -0.10
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.72M
Short Ratio 1.49
Short % of Float 2.85%
Beta 0.31
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 5.34
PB Ratio 6.56
Revenue 38.98M
Operating Income -5.38M
Net Income -9.95M
Free Cash Flow -6.57M
Net Cash -7.71M
Net Cash / Share -0.11
Gross Margin 55.56%
Operating Margin -13.81%
Profit Margin -25.50%
FCF Margin -16.86%
ROA -6.30%
ROE -30.78%
ROIC -36.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$8.50*
(177.78% upside)
Low
6.00
Current: $3.06
High
13.00
Target: 8.50
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue31.8015.8613.6622.1332.6024.4931.4635.0318.5722.22
Revenue Growth100.47%16.18%-38.29%-32.13%33.13%-22.15%-10.21%88.71%-16.46%-
Gross Profit21.668.777.0213.3518.9713.1217.5020.629.8712.92
Operating Income-6.44-16.89-8.493.026.623.929.7910.943.304.35
Net Income-12.02-23.94-6.610.344.352.4314.3415.305.406.74
Shares Outstanding63.3253.8634.6428.6728.5328.5228.3827.6927.2926.98
Earnings Per Share-0.19-0.44-0.250.010.150.080.500.530.190.24
EPS Growth----93.33%87.5%-84%-5.66%178.95%-20.83%-
Dividend Per Share-----0.210.200.220.200.15
Dividend Growth-----5%-9.09%10%33.33%-
Operating Cash Flow-5.49-11.550.98-1.71-1.553.6711.7910.366.973.99
Capital Expenditures-0.11-0.05-0.13-0.01-0.14-0.10-0.30-0.72-0.05-0.05
Free Cash Flow-5.59-11.600.85-1.72-1.683.5711.499.646.923.94
Cash & Equivalents6.303.763.282.394.115.808.925.304.322.92
Total Debt8.279.39-------0.01
Net Cash / Debt-1.98-5.633.282.394.115.808.925.304.322.91
Assets53.6348.4555.3438.6237.4731.6735.1730.4519.4418.37
Liabilities21.3018.976.884.694.343.613.776.232.692.24
Book Value32.3329.4848.4533.9333.1328.0731.4024.2216.7516.13
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Veru Inc.
Country United States
Employees 386
CEO Mitchell Shuster Steiner

Stock Information

Ticker Symbol VERU
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: VERU
IPO Date July 19, 1990

Description

Veru Inc., an oncology and urology biopharmaceutical company, engages in developing novel medicines for prostate cancer treatment and prostate cancer supportive care. The company's oncology drug candidates include VERU-111, an oral alpha and beta tubulin inhibitor, which is in a development Phase 1b/2 for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a Phase 2 clinical trial for the treatment of hot flashes in men undergoing androgen deprivation therapies; and VERU-100, a GnRH antagonist that is in planned Phase 2 clinical trial for the palliative treatment of advanced prostate cancer. Its urology specialty drug candidates are TADFIN, a tadalafil and finasteride combination of tablets and capsules for the treatment of men with lower urinary tract symptoms; and Tamsulosin XR capsules, which are tamsulosin capsules for treating benign prostatic hyperplasia. The company's commercial products include the FC2 Female/Internal condoms for the prevention of pregnancy and sexually transmitted infections; and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation. Its customers primarily include international agencies, government health agencies, ministries of health, and other governmental agencies, which purchase and distribute FC2 for use in HIV/AIDS prevention and family planning programs; and telemedicine providers who sell into the prescription channel in the United States. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. is headquartered in Miami, Florida.